非酒精性脂肪肝病之臨床病程、風險因子及預後

The Clinical Courses, Risk Factors, and Prognosis of Non-Alcoholic Fatty Liver Disease

楊盈盈(Ying-Ying Yang)

《台灣醫學》 26卷3期 (2022/05) Pp. 322-327

https://doi.org/10.6320/FJM.202205_26(3).0006

摘要

從1980年開始，非酒精性脂肪肝疾病及非酒精性脂肪肝炎NAFLD-NASH疾病的病理機轉假設，從兩個連續的疾病風險因子所造成的疾病進展，已漸漸移至多重並行疾病因子造成的疾病進展，最近有很多研究發現代謝症候群跟NAFLD-NASH有些相關性，另外最近學界新共識的新名詞為代謝異常症候群相關的脂肪肝疾病（MAFLD），這新名詞被廣泛的用在相關的疾病論述裡面，另外有25%健康的肝臟隨著環境、飲食因素漸漸進展到脂肪肝，6.3%可能隨著持續的環境跟飲食因素會進展到NAFLD-NASH甚至到肝硬化或肝癌，直到最近有許多資料顯示NAFLD-NASH疾病機轉上是由多重並行的疾病路徑所造成，所以在治療上必須要多重的治療途徑進行，才可減少相關的疾病進展，以及相關的併發症發生。

關鍵字

非酒精性脂性肝炎 ； 代謝症候群相關的脂肪肝的疾病 ； 肝硬化 ； 肝癌

並列摘要

Since 1980, the pathogenesis of NAFLD-NASH had shifted from two-hit hypothesis to hypothesis of multiple parallel hits. Recent study established the relationship between metabolic syndrome and NAFLD-NASH and the new term of metabolic dysfunction fatty liver disease (MAFLD) had been widely used. 25% of healthy livers will progress to fatty livers and 6.3% progress to NAFLD-NASH, cirrhosis and hepatocellular carcinoma. Until recently, it is well-established that multi-pathways approaches are required for management of NAFLD-NASH or MAFLD and their related complications.

並列關鍵字

nonalcoholic steatohepatitis ； metabolic dysfunction fatty liver disease ； cirrhosis ； hepatocellular carcinoma

參考文獻

Geier A, Tiniakos D, Denk H, et al. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021;70:1570-9.

Hsu CS, Kao JH. Non-alcoholic fatty liver disease: An emerging liver disease in Taiwan. J Formos Med Assoc 2012;111:527-35.

Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202-9.

Eslam M, Sanyal AJ, George J. Toward more accurate nomenclature for fatty liver diseases. Gastroenterology 2019;157:590-3.

Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.